Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.
Viracta Therapeutics, Inc. (VIRX) has issued a series of news releases that trace its evolution from an active clinical-stage precision oncology company to an organization in wind down. Company announcements describe a focus on virus-associated cancers, particularly Epstein-Barr virus (EBV)-positive lymphomas and solid tumors, and provide detailed updates on its lead product candidate, Nana-val, an all-oral combination of nanatinostat and valganciclovir.
News items have covered multiple aspects of Viracta’s development programs, including clinical data from the Phase 2 NAVAL-1 trial in relapsed or refractory EBV-positive lymphomas and from a Phase 1b/2 study in EBV-positive nasopharyngeal carcinoma and other advanced EBV-positive solid tumors. The company has reported positive antitumor activity and a generally well-tolerated safety profile for Nana-val in certain EBV-positive peripheral T-cell lymphoma (PTCL) populations, as well as productive regulatory interactions with the U.S. Food and Drug Administration regarding potential paths to registration.
Corporate and strategic developments are also documented in Viracta’s news flow. Releases describe resource reprioritizations, reductions in force, and a resizing of the board of directors as the company sought to conserve cash and focus on its EBV-positive lymphoma program. Later communications announce the closure of the pivotal NAVAL-1 trial while the board explores strategic alternatives, and ultimately, the termination of employees and a decision to wind down operations, with continued exploration of options for the development programs.
On Stock Titan’s VIRX news page, readers can review this sequence of clinical, regulatory, and corporate updates directly from Viracta’s public disclosures. This provides historical context on Nana-val’s development, Viracta’s precision oncology strategy in EBV-associated cancers, and the subsequent decisions to close trials, explore strategic alternatives, and wind down operations.
Viracta Therapeutics (Nasdaq: VIRX) announced the first patient dosing in the Phase 1b/2 trial of its all-oral combination therapy Nana-val (nanatinostat and valganciclovir) for patients with EBV-positive recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). This trial aims to evaluate Nana-val's safety and efficacy, both alone and in combination with pembrolizumab. The need for effective treatment options is critical as advanced NPC patients face poor outcomes. The trial includes a dose escalation phase and a dose expansion cohort for other advanced EBV+ solid tumors.
Viracta Therapeutics (Nasdaq: VIRX), a precision oncology firm, announced its upcoming presentation at the H.C. Wainwright BIOCONNECT Virtual Conference scheduled for January 10, 2022, starting at 7:00 a.m. ET. The pre-recorded webcast will be accessible on-demand at the Viracta website and will be archived for 90 days.
Viracta is focusing on virus-associated malignancies with its investigational drug, nanatinostat, currently in pivotal trials for EBV-positive lymphoma and other related cancers.
Viracta Therapeutics, Inc. (Nasdaq: VIRX) has been selected for addition to the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. The NBI tracks biotechnology and pharmaceutical securities on the Nasdaq and is re-ranked annually through a modified capitalization-weighted methodology. Viracta focuses on precision oncology targeting virus-associated malignancies, with its investigational drug nanatinostat currently in trials for EBV-positive lymphoma and nasopharyngeal carcinoma.
Viracta Therapeutics (Nasdaq: VIRX) presented new preclinical data on vecabrutinib, a reversible inhibitor of Bruton's tyrosine kinase (BTK), at the 2021 ASH Annual Meeting. Key findings from the oral presentation indicate vecabrutinib enhances the efficacy and safety of CART19 cell therapy, potentially leading to improved long-term responses in hematological malignancies. Additionally, a poster presentation highlighted vecabrutinib's effectiveness in reducing symptoms of cGVHD. The company aims to explore clinical development options for combining vecabrutinib with CART19.
Viracta Therapeutics (Nasdaq: VIRX) has presented final data from its Phase 1b/2 trial of Nana-val for relapsed/refractory EBV+ lymphoma at the 2021 ASH Annual Meeting. The trial included 55 patients, showing a 40% overall response rate (ORR) and a 19% complete response (CR) rate. Notably, the median duration of response (DoR) was 10.4 months, indicating promising durability. Nana-val was generally well tolerated. The company highlighted the trial's potential to address unmet needs in EBV-associated cancers and plans to advance into the NAVAL-1 registration-enabling study.
Viracta Therapeutics (Nasdaq: VIRX) announced that the FDA has granted orphan drug designation for its oral product candidate, nanatinostat and valganciclovir (Nana-val), aimed at treating Epstein Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL). DLBCL represents about 25% of non-Hodgkin lymphoma cases in the U.S. The orphan drug status facilitates development, offering benefits like tax credits and market exclusivity. Currently, Viracta is conducting the NAVAL-1 trial to evaluate Nana-val's effectiveness in EBV+ DLBCL patients, with enrollment sites open in the U.S., Europe, and Asia.
Viracta Therapeutics (Nasdaq: VIRX) announced its Q3 2021 financial results, highlighting notable advancements, including the initiation of an EBV-positive solid tumor trial and reacquisition of Nana-val’s rights in China. The company ended the quarter with approximately $111 million in cash and is on track to exceed $100 million by year-end 2021. Key clinical updates include the expansion of the NAVAL-1 trial and positive preliminary results for Nana-val in EBV-positive lymphoma. Viracta is positioned to advance its clinical trials and maintain strong financial health into 2024.
Viracta Therapeutics (Nasdaq: VIRX) has secured a $50.0 million credit facility from Silicon Valley Bank and Oxford Finance. This facility replaces a previous $15.0 million loan agreement, refinancing $5.0 million of existing debt. The new credit line allows for additional tranches of $20.0 million and $25.0 million, providing the company with non-dilutive financing and enhancing operational flexibility. The funding is expected to support upcoming clinical trials and advance the company's vaccine technology targeting virus-associated cancers.
Viracta Therapeutics (Nasdaq: VIRX) has announced the acceptance of three abstracts for presentation at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. This includes two oral presentations on the final results of their Phase 1b/2 trial for EBV positive lymphoma and the application of vecabrutinib in CAR T cell therapies, along with a poster presentation on vecabrutinib's efficacy in a murine model of graft-versus-host disease. This recognition highlights the innovative progress in Viracta's therapeutic pipeline.
Viracta Therapeutics (NASDAQ: VIRX) is set to present at multiple investor conferences in November 2021. Key events include:
- Credit Suisse 30th Annual Healthcare Conference: Nov 8-12, Presentation on Nov 11 at 1:50 PM ET.
- Jefferies London Healthcare Conference: Nov 16-17, Presentation on Nov 17 at 10:40 AM GMT.
- Piper Sandler 33rd Annual Healthcare Conference: Nov 29-Dec 2, Presentation on Nov 22.
- Evercore ISI 4th Annual HealthCONx Conference: Nov 29-Dec 2, Presentation on Dec 2 at 3:55 PM ET.
Webcasts will be available on their website.
FAQ
What is the current stock price of Viracta Therapeutics (VIRX)?
What is the market cap of Viracta Therapeutics (VIRX)?
